The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ZUMA-5: 5-year follow-up analysis of axicabtagene ciloleucel in patients with R/R iNHL
|
Axi-cel, a CD19-directed chimeric antigen receptor T-cell therapy, was approved by the European Commission for the treatment of patients with R/R FL based on results from the phase II ZUMA-5 trial (NCT03105336). ZUMA-5 is a multicenter trial evaluating the efficacy and safety of axi-cel in patients with R/R iNHL, including FL and MZL, who have failed ≥2 prior lines of therapy. 5-year follow-up results from the trial (N = 159; FL: n = 127 for efficacy, n = 124 for safety; MZL: n = 31 for efficacy, n = 28 for safety) were presented at the 66th ASH Annual Meeting and Exposition by Neelapu.1 |
| Key learnings |
| The ORR was 90%; 94% in patients with FL and 77% in patients with MZL. The CR rate was 75% overall; 79% in patients with FL and 65% in patients with MZL. |
| The median PFS was 62.2 months overall, and 57.3% in patients with FL. The 60-month PFS rates were 50.4% overall and 49.8% in patients with FL, regardless of high-risk factors including POD24. |
| The median OS was not reached, with a 60-month OS rate of 69.0% overall. In patients with FL, the 60-month lymphoma-specific OS rate was 83.4%. The median DoR was 60.4 months, with a 60-month DoR of 53.4%. |
| Safety outcomes were consistent with previous analyses, with no new safety signals reported. |
| This 5-year follow-up of the ZUMA-5 trial demonstrates durable responses of axi-cel in patients with R/R iNHL, with curative potential in patients with R/R FL and promising efficacy in high-risk R/R FL. |
Abbreviations: Axi-cel, axicabtagene ciloleucel; CR, complete response; DoR, duration of response; FL, follicular lymphoma; iNHL, indolent non-Hodgkin lymphoma; MZL, marginal zone lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
